Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02040623

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) — DROPS-2  

Chronic Graft-versus-host Disease Clinical Trial

Official title:
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions for the Treatment of Keratoconjunctivitis Sicca in Patients With Chronic Ocular Graft Versus Host Disease

Clinical Trial Summary

- To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures.

- To investigate the safety and tolerability of R348 Ophthalmic Solutions administered for 12 weeks to subjects.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02040623
Study type Interventional
Source Rigel Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date March 2014
Completion date July 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT02991846 - A Prospective Observational Study for Evaluating CGVHD
Recruiting NCT02291770 - Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells Phase 3
Terminated NCT01226420 - Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease Phase 2
Active, not recruiting NCT02759731 - Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Completed NCT01862965 - Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus Phase 2
Completed NCT02411474 - Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD N/A
Active, not recruiting NCT01158105 - Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD) Phase 2
Terminated NCT01903473 - Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) Phase 2
Active, not recruiting NCT01366092 - Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease Phase 2
Not yet recruiting NCT06458127 - Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease N/A
Recruiting NCT05690971 - Psychosocial Mobile App for Chronic Graft-Versus-Host Disease N/A
Recruiting NCT02918188 - Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD Phase 2
Recruiting NCT01765660 - Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease Phase 2
Completed NCT01956903 - Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell. Phase 1/Phase 2
Terminated NCT03584516 - GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Phase 2/Phase 3
Recruiting NCT04692376 - MSC for Treatment of cGVHD After Allo-HSCT Phase 2
Completed NCT02966301 - Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide Phase 2
Terminated NCT01898377 - Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children Phase 2
Recruiting NCT02611180 - Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Recruiting NCT02669251 - Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Phase 1/Phase 2